Physician profile
Simon K Wright
NPI 1710945506
$20,534.39
in general payments reported to CMS, 2019-2025
36 companies · $1,966 in 2025
The $1,966 reported for 2025 was more than what 89% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,019 · 2020: $5,765 · 2021: $5,439 · 2022: $1,706 · 2023: $749 · 2024: $3,891 · 2025: $1,966.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $4,284 · Food and Beverage: $2,322.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $4,283.66 |
| Food and Beverage | $2,322.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $6,177.83 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $4,516.53 | 2019-2025 | Dupixent |
| Intuitive Surgical, INC. | $4,385.33 | 2024-2025 | |
| Medical Device Business Services, INC. | $1,088.68 | 2022 | |
| Intersect Ent, INC. | $1,082.95 | 2019-2022 | |
| Aerin Medical INC. | $636.00 | 2020-2025 | |
| Acclarent, INC | $462.41 | 2019-2022 | |
| Optinose US, INC. | $294.20 | 2019-2025 | |
| Stryker Corporation | $225.85 | 2019-2024 | Scopis Ent |
| Phathom Pharmaceuticals, INC. | $195.63 | 2025 | Voquezna |
| Karl Storz Endoscopy-America | $189.88 | 2019-2023 | |
| Inspire Medical Systems, INC. | $166.23 | 2024 | Inspire |
| Itamar Medical INC | $161.17 | 2022-2025 | Watchpatone |
| Medtronic USA, INC. | $150.00 | 2020 | |
| Microtransponder, INC. | $140.68 | 2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $108.58 | 2019-2021 | |
| Organogenesis INC. | $65.90 | 2023-2025 | Puraply, Puraply Wound Matrix |
| Neurent Medical Limited | $62.41 | 2024-2025 | Neuromark Radiofrequency Console, Neuromark Device, Neuromark System |
| Integra Lifesciences Corporation | $49.58 | 2025 | Trudi Probe, Inspira Air, Acclarent Aera |
| Hologic Sales and Service, LLC | $45.72 | 2023-2025 | Coolseal Generator |
| Alk-Abello, INC | $44.14 | 2021-2022 | |
| Smith+Nephew, INC. | $42.61 | 2022-2024 | Tula |
| Astrazeneca Pharmaceuticals LP | $32.79 | 2025 | Tezspire |
| Depuy Synthes Sales INC. | $28.74 | 2025 | Matrixmidface, Matrixmandible |
| Amgen INC. | $23.13 | 2025 | |
| Novartis Pharmaceuticals Corporation | $21.74 | 2025 | |
| Medtronic, INC. | $21.60 | 2021 | |
| Ethicon US, LLC | $18.51 | 2025 | Stratafix |
| Ars Pharmaceuticals Operations, INC. | $18.14 | 2025 | Neffy |
| Xoran Technologies LLC | $16.50 | 2021 | |
| Zimmer Biomet Holdings, INC. | $16.06 | 2019 | |
| Cochlear Americas | $15.23 | 2021 | |
| Agiliti Surgical, INC. | $14.97 | 2019 | |
| Kaleo, INC. | $14.67 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simon Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.